Regeneron Pharmaceuticals, Inc. (REGN)
$18.24
0.15 (+0.83%)
| CAPS Rating |
|
|---|---|
| Open | $18.15 |
| Previous Close | $18.09 |
| Daily Range | $18.12 - $18.43 |
| 52-Week Range | $11.81 - $23.49 |
| Market Cap | $1.47B |
| P/E Ratio | 0.00 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 319,297 |
| Average Daily Volume | 727,000 |
REGN
VS S&P 500 (SPY)
How do you think REGN will perform vs the S&P 500?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
REGN Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
REGN News and Commentary
- 4 Platform Drugmakers to Invest In – The Motley Fool
- Drug Companies Should Think Smaller – The Motley Fool
- Now That's What I Call a Drug Deal – The Motley Fool
- UPDATE 1-Regeneron, Sanofi, expand drug partnership – Reuters
- Nexavar, and Onyx, Nail It – The Motley Fool
- More Tests for Drug for Cancer Patients – The Motley Fool
- A Meaningless FDA Approval ... for Now – The Motley Fool
- 5 Deathbed Stocks? – The Motley Fool
- Cruising, but Ready to Take Off – The Motley Fool
- Late to the Party – The Motley Fool
- A Top BioMarin Drug Heads Overseas – The Motley Fool
- Regeneron's Results Clearing Up – The Motley Fool
- BioMarin's New Drugs Mostly Hit Their Targets – The Motley Fool
- 7 Stocks Defying the Doubters – The Motley Fool
- FDA Approvals ... Increase? – The Motley Fool
- Regeneron's Orphan Charms the FDA – The Motley Fool
- Surprising Low-Rated Stocks the Leaders Love – The Motley Fool
- Regeneron Sees Positive Phase 2 Data – The Motley Fool
- This Just In: Upgrades and Downgrades – The Motley Fool
- Contrarian Shopping List – The Motley Fool
RSS Headlines
Fool UK
